10048556AI Design for Personalised Digital Therapy for early dementiaClosedCollaborative R&DInnovate UKDementia is an increasing problem as people benefit from longer lifespans but lose cognitive senses and physical coordination with age. With medication only able to alleviate symptoms, the burden on the healthcare system and family support networks has grown rapidly. There are presently 47m people worldwide living with dementia and by 2030 this number will be 75m. Every 3 seconds, a patient develops dementia, and there are 10 million new cases every year around the globe. The early intervention market is currently $818bn which is expected to rise to $2 trillion by 2030, because there is no cure of any types of dementia currently and it is an untapped market since the industry focuses on diagnosis & drug delivery for dementia. The current treatment of dementia comprises the use of anti-dementia drugs for Alzheimer's disease only, and the therapeutic needs of people with early dementia including preclinical dementia and mild cognitive impairment (MCI) remain highly unmet. The need for a cognitive improvement system for pre-symptoms & early dementia patients is unmet since no treatment is available especially for dementia. The proposed neurofeedback system is a self-management solution but also a therapeutic system that provides a cognitive map response for each game played which includes (1) cognitive scores and (2) brain profile responses. The cognitive map produced will help the user, carer and the clinician to understand the patients' cognitive enhancement and the brains' current capacity to adapt and prevent the dementia symptoms as a secondary tool. The benefits of the technology are: (1) non-invasive; (2) improved mental ability for dementia patients; (3) can provide early dementia treatment; (4) ensures patient's longer independence; (5) reduced reliance upon NHS and improves UK economy; and (6) will strengthen the UK as a leader in dementia research.